Supriya Lifescience liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022

5.32×	5.32×	5.17×	4.85×	4.99×
3.88×	3.88×	4.06×	3.64×	4.06×
76.1	76.1	68.3	85.3	166
355	355	321	369	398

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health

₹ CrorePeersSTAR SPARC THYROCARE SHILPAMED VIYASH RUBICON YATHARTH PARKHOSPS

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	Last 12M 30/06/2026
Current Ratio	4.99	4.85	5.17	5.32	5.32
Quick Ratio	4.06	3.64	4.06	3.88	3.88
Cash, Equiv & ST Investments	165.8	85.3	68.3	76.1	76.1
Working Capital	397.8	369.1	320.9	354.9	354.9

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.